Axon Enterprise, Inc. (NASDAQ:AXON) Position Trimmed by Creative Planning

Creative Planning lowered its stake in Axon Enterprise, Inc. (NASDAQ:AXON) by 4.8% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 15,678 shares of the biotechnology company’s stock after selling 785 shares during the period. Creative Planning’s holdings in Axon Enterprise were worth $6,265,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of AXON. Blue Trust Inc. raised its position in shares of Axon Enterprise by 987.5% during the second quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 79 shares during the period. Trivant Custom Portfolio Group LLC acquired a new stake in Axon Enterprise during the 1st quarter worth about $31,000. Quent Capital LLC lifted its stake in Axon Enterprise by 1,875.0% during the third quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 75 shares in the last quarter. Asset Dedication LLC acquired a new position in shares of Axon Enterprise in the second quarter worth about $47,000. Finally, Cullen Frost Bankers Inc. purchased a new position in shares of Axon Enterprise in the second quarter worth approximately $59,000. Institutional investors and hedge funds own 79.08% of the company’s stock.

Insider Activity

In related news, CEO Patrick W. Smith sold 80,300 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $371.78, for a total value of $29,853,934.00. Following the completion of the sale, the chief executive officer now directly owns 3,015,366 shares in the company, valued at approximately $1,121,052,771.48. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Axon Enterprise news, CEO Patrick W. Smith sold 80,300 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $371.78, for a total transaction of $29,853,934.00. Following the completion of the transaction, the chief executive officer now owns 3,015,366 shares of the company’s stock, valued at $1,121,052,771.48. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $437.98, for a total value of $437,980.00. Following the completion of the sale, the director now directly owns 26,259 shares in the company, valued at approximately $11,500,916.82. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 371,172 shares of company stock valued at $137,000,162. Insiders own 6.10% of the company’s stock.

Axon Enterprise Stock Performance

AXON stock opened at $442.69 on Thursday. The company has a market capitalization of $33.45 billion, a price-to-earnings ratio of 116.81, a P/E/G ratio of 11.74 and a beta of 0.94. The firm has a 50 day moving average of $393.29 and a two-hundred day moving average of $334.66. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 0.35. Axon Enterprise, Inc. has a 12 month low of $199.29 and a 12 month high of $455.17.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.18. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The firm had revenue of $504.00 million during the quarter, compared to analysts’ expectations of $478.35 million. During the same period in the prior year, the company posted $0.80 earnings per share. Axon Enterprise’s revenue for the quarter was up 34.5% on a year-over-year basis. As a group, equities analysts anticipate that Axon Enterprise, Inc. will post 1.79 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. The Goldman Sachs Group upped their price target on shares of Axon Enterprise from $385.00 to $441.00 and gave the company a “buy” rating in a research report on Wednesday. JMP Securities raised their target price on Axon Enterprise from $375.00 to $430.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. Craig Hallum upped their price target on Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Northland Securities raised their price objective on Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research report on Thursday, August 8th. Finally, Jefferies Financial Group assumed coverage on Axon Enterprise in a report on Wednesday, July 17th. They issued a “buy” rating and a $385.00 target price on the stock. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $382.85.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.